Home Featured Page 107

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy”...

BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression...

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at...

PT422 – Curative Mushrooms: Exploring the World of Grow Kits and...

Psyence Appoints Intellectual Property Expert to Its Board of Directors

Numinus to Present at the Small Cap Growth Virtual Investor Conference...

Bright Minds Announces Effective Date of Share Consolidation

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine...

Psychedelic Research Bulletin: June 2023

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy”...

BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression...

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at...

PT422 – Curative Mushrooms: Exploring the World of Grow Kits and...

Psyence Appoints Intellectual Property Expert to Its Board of Directors

Numinus to Present at the Small Cap Growth Virtual Investor Conference...

Bright Minds Announces Effective Date of Share Consolidation

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine...

Psychedelic Research Bulletin: June 2023

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY